These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 636683)

  • 1. Animal models for screening hypolipidemic drugs. III. The response of nicotinic acid and clofibrate in fed and fasted old rats.
    Magnusson O; Andersson I; Nordlund L
    Z Versuchstierkd; 1978; 20(1):46-58. PubMed ID: 636683
    [No Abstract]   [Full Text] [Related]  

  • 2. Animal models for screening hypolipidemic drugs. II. Response to nicotinic acid in the Mongolian gerbil. Short communication.
    Magnusson O
    Z Versuchstierkd; 1978; 20(1):41-5. PubMed ID: 636682
    [No Abstract]   [Full Text] [Related]  

  • 3. Animal models for screening hypolipidemic agents. I. Response to clofibrate in NMRI-mice of different body-weights.
    Magnusson O
    Z Versuchstierkd; 1978; 20(1):35-40. PubMed ID: 636681
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W; Schultz A
    Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of a lipid-reducing clofibrate-inositolnicotinate combination compared to clofibrate. A double-blind study].
    Schäfer B; Kluthe R
    Med Welt; 1975 Apr; 26(14):655-63. PubMed ID: 1099394
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats.
    Cayen MN; Robinson WT; Dubuc J; Dvornik D
    Biochem Pharmacol; 1979 Apr; 28(7):1163-7. PubMed ID: 444274
    [No Abstract]   [Full Text] [Related]  

  • 7. [Correction of lipid metabolism disorders in glomerulonephritis].
    Pyrig LA; Mel'man NIa; Petrun' NM; Nikulina GG; Romaniuk GV
    Klin Med (Mosk); 1981 Nov; 59(11):49-53. PubMed ID: 7321498
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mechanism of action of drugs affecting lipid metabolism].
    Rossini L
    Minerva Med; 1975 Oct; 66(66):3458-68. PubMed ID: 1178137
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
    Jacotot B
    Sem Hop; 1979 Dec 8-15; 55(41-42):1947-55. PubMed ID: 231322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
    Maroto ML; Priego JG; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preliminary study of the effects of nicotinic-N-oxide acid causing hypolipidemia administered alone or in combination with clofibrate].
    Palamara G; De Luca G; Materazzi M
    Boll Chim Farm; 1977 Oct; 116(10):596-600. PubMed ID: 607948
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypolipidemic activity of Indan--1--acetic acids.
    Adak M; Gupta JK
    Nepal Med Coll J; 2006 Mar; 8(1):22-6. PubMed ID: 16827085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and hypolipidemic activity of some new esters of glycerol and 2-O-methyl-glycerol with nicotinic and 5-fluoro-nicotinic acids.
    Dall'Asta L; Comini A; Borella F; Berti MA; Coppi G
    Boll Chim Farm; 1989 Mar; 128(3):106-10. PubMed ID: 2775523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] lipid metabolism. II. Effects on the incorporation of various isotopic precursors in rat liver].
    Priego JG; Maroto ML; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):28-30. PubMed ID: 697397
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug interactions and side effects of hypolipidemic drugs.
    Schwandt P
    Int J Clin Pharmacol Biopharm; 1979 Aug; 17(8):351-6. PubMed ID: 489202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental hypolipidemic and antiatherosclerotic activity of bisanions].
    Ryzhenkov VE; Khromov-Borisov NV; Mosina IV; Indenbom ML
    Farmakol Toksikol; 1979; 42(6):632-5. PubMed ID: 499472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats.
    Ohata I; Sakamoto N; Nitatori R; Maeno H
    Arzneimittelforschung; 1983; 33(2):237-41. PubMed ID: 6682662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
    Gustafsson K; Kiessling H
    Z Versuchstierkd; 1982; 24(5-6):262-70. PubMed ID: 7170838
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
    Högberg T; Bondesson G; Stjernström NE
    Acta Pharm Suec; 1977; 14(2):149-60. PubMed ID: 906832
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential hypolipidemic agents. XIX. Synthesis and lipid-lowering properties of thiophene derivatives related to clofibrate.
    Gronowitz S; Svenson R; Bondesson G; Magnusson O; Stjernström NE
    Acta Pharm Suec; 1978; 15(5):361-7. PubMed ID: 747094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.